Since 2021, the FDA has approved two CAR-T therapies for multiple myeloma. These new treatments offer potential options for patients with relapsed/refractory multiple myeloma. Ongoing clinical trials continue to explore promising new applications of CAR-T therapies. Read on to learn more about the effect of CAR-T cell therapy on multiple myeloma. What is CAR-T Therapy?